• Celldex discontinued its Phase 2 prurigo nodularis trial of barzolvolimab after missing the primary endpoint at Week 12.
• Key secondary endpoints also missed. Results did not differentiate from placebo. No improvement seen through Week 24.
• Safety profile remained favorable. New 450 mg loading dose followed by 150 mg or 300 mg every four weeks was well tolerated.
• Serum tryptase dropped sharply, signaling systemic mast cell depletion. The biomarker effect did not translate into symptom improvement in prurigo nodularis.
• Phase 3 chronic spontaneous urticaria topline data expected in Sept/Oct 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607211601PRIMZONEFULLFEED9765714) on July 21, 2026, and is solely responsible for the information contained therein.